financetom
Business
financetom
/
Business
/
What's Going On With Rumble Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Rumble Stock Today?
Mar 25, 2025 7:41 AM

Rumble Inc. ( RUM ) shares are trading lower on Tuesday.

The company reported fourth-quarter sales of $30.20 million (+48% year over year), beating the analyst consensus estimate of $29.73 million.

Average Revenue Per User for the fourth quarter was $0.39, compared to $0.33 in the third quarter, an increase of 18%.

The increase from the third quarter is attributable to higher advertising and subscription revenue.

Adjusted EBITDA was a loss of $13.4 million, representing an improvement of $16.6 million year over year.

As of December 31, Rumble’s balance of cash and equivalents was approximately $114.0 million.

Average global Monthly Active Users was 68 million in the fourth quarter of 2024, compared to 67 million in the third quarter. 

Also Read: Massachusetts Regulator Opens Investigation Into Robinhood’s Sports Betting Feature

Rumble’s Chairman and CEO Chris Pavlovski commented, “While I am pleased with our topline quarterly growth of 48% year over year, I am even more impressed with the third to fourth quarter growth in U.S. and Canada MAUs of 21% to 52 million.”

Rumble’s Board of Directors approved a $20 million strategy to diversify the company’s cash reserves into Bitcoin.

The company said this move highlights Rumble’s belief in Bitcoin’s value and its plans to expand into cryptocurrency.

“As I look ahead, with the Tether transaction now closed, I could not be more excited about the possibilities and the new era we are entering for Rumble,” Pavlovski added.

The company reported a loss per share of $1.15, which may not be comparable to the consensus loss of $0.12.

Outlook: For the first quarter, the company expects at least 25% revenue growth year over year.

It is also moving towards Adjusted EBITDA breakeven in 2025, with the new capital from Tether providing increased flexibility to invest in initiatives that may accelerate and expand the business.

Price Action: RUM shares are trading lower by 1.11% to $7.921 at last check Tuesday.

Read Next:

Pony AI Q4: Revenue Slumps Nearly 30% As Robotaxi Sales Decline, Loss Widens

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fifth Third Ban Insider Sold Shares Worth $327,526, According to a Recent SEC Filing
Fifth Third Ban Insider Sold Shares Worth $327,526, According to a Recent SEC Filing
Oct 30, 2024
05:57 PM EDT, 10/29/2024 (MT Newswires) -- Kristine R. Garrett, EVP, on Oct. 28, sold 7,500 shares in Fifth Third Ban (FITB) for $327,526. Following the Form 4 filing with the SEC, Garrett has control over a total of 55,913 shares of the company, with 55,913 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/35527/000003552724000240/xslF345X05/wk-form4_1730236933.xml ...
First Horizon Board Approves $1 Billion Share Repurchase Program
First Horizon Board Approves $1 Billion Share Repurchase Program
Oct 30, 2024
05:57 PM EDT, 10/29/2024 (MT Newswires) -- First Horizon ( FHN ) said late Tuesday its board authorized a new $1 billion common stock repurchase program that will expire Jan. 31, 2026. The authorization replaces its previous repurchase program, which had roughly $174 million of remaining authorization and was scheduled to expire Jan. 31, 2025. The board kept its quarterly...
Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14
Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14
Oct 30, 2024
10:57 AM EDT, 10/30/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Wednesday that the US Food and Drug Administration has accepted the biologic license application for HLX14, an investigational biosimilar of denosumab. Denosumab is approved in several countries for different indications including the treatment of osteoporosis in postmenopausal women, the companies said. Organon secured the exclusive commercialization...
bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method
bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method
Oct 30, 2024
10:42 AM EDT, 10/30/2024 (MT Newswires) -- bioAffinity Technologies (BIAF) said Wednesday it received a Japanese patent for its CyPath Lung diagnostic test method, which predicts lung cancer risk. The patent expands bioAffinity's portfolio to 17 granted patents, the company said. Shares of bioAffinity rose 2.7% in recent trading. Price: 1.34, Change: +0.03, Percent Change: +2.69 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved